Cognition Therapeutics, Inc. announced that its Phase 2 'START' Study of zervimesine (CT1812) in early Alzheimer's disease has surpassed the 50% enrollment target. The study is being conducted in collaboration with the Alzheimer’s Clinical Trials Consortium (ACTC) and is supported by an $81 million grant from the National Institute on Aging (NIA).
The START Study is designed to enroll up to 540 individuals with mild Alzheimer’s disease, who will receive zervimesine or placebo for 18 months. Participants are being enrolled at approximately 50 sites across the United States.
This milestone reflects strong interest from patients and investigators in a convenient, once-daily oral treatment with a novel approach to addressing amyloid in early Alzheimer’s disease. The company aims to build an understanding of zervimesine’s potential across the Alzheimer’s spectrum, following positive results from the SHINE Study in mild-to-moderate AD.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.